FORM 6-K


U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of May 2020

 Commission File Number: 001-38757
TAKEDA PHARMACEUTICAL COMPANY LIMITED
(Translation of registrant’s name into English)

1-1, Nihonbashi-Honcho 2-Chome
Chuo-ku, Tokyo 103-8668
Japan
(Address of principal executive offices)


Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F  ☒            Form 40-F  ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐





Information furnished on this form:
EXHIBIT



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Date: May 15, 2020 By: /s/ Takashi Okubo
Takashi Okubo
Global Head of Investor Relations



        





News Release



Takeda Announces Candidates for New Directors

Osaka, Japan, May 15, 2020, --- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has decided the candidates for new Directors which will be proposed to the 144th Ordinary General Meeting of Shareholders in June 2020. The candidates are as follows;

1.Candidates for Non-Audit and Supervisory Committee Directors
Name Category Current Role
Christophe Weber Internal Existing
Representative Director,
President & Chief Executive Officer
Masato Iwasaki Internal Existing Director, President, Japan Pharma Business Unit
Andrew Plump Internal Existing Director, President, Research & Development
Constantine Saroukos
Internal Existing Director, Chief Financial Officer
Masahiro Sakane External Existing External Director, Chair of the Board Meeting
Olivier Bohuon External Existing External Director
Jean-Luc Butel External Existing
External Director
Ian Clark External Existing External Director
Yoshiaki Fujimori External Existing External Director
Steven Gillis External Existing External Director
Shiro Kuniya External Existing External Director
Toshiyuki Shiga External Existing External Director






2.Candidates for Audit and Supervisory Committee Directors
Name Category Current Role
Yasuhiko Yamanaka
Internal
Existing
Director, Full-time Audit & Supervisory Committee member
Koji Hatsukawa
External
Existing External Director, Chairperson of Audit & Supervisory Committee
Emiko Higashi External Existing External Director, Audit & Supervisory Committee member
Michel Orsinger External Existing External Director, Audit & Supervisory Committee member

Media Contact:
Kazumi Kobayashi
kazumi.kobayashi@takeda.com
+81 (0) 3-3278-2095


###


Takeda Pharmaceutical (PK) (USOTC:TKPHF)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025 Plus de graphiques de la Bourse Takeda Pharmaceutical (PK)
Takeda Pharmaceutical (PK) (USOTC:TKPHF)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025 Plus de graphiques de la Bourse Takeda Pharmaceutical (PK)